invIOs Publishes Positive Phase 1 Clinical Data for Cancer Immunotherapy APN401

invIOs GmbH has published positive Phase 1 clinical data for its autologous CBL-B-silenced cell therapy, APN401, in patients with advanced, treatment-refractory solid tumors. The study, published in Molecular Therapy Oncology, reported a favorable safety profile and observed disease stabilization in a subset of patients.